Carlyle’s Exit from Viyash Scientific On 26 August, promoters CA Hull Investments and CA Harbor Investments, both part of The Carlyle Group, off‑loaded a 10.88 percent stake in Hyderabad‑based Viyash Scientific (formerly Sequent Scientific). The sale involved 4.75 crore equity shares, valued at Rs 1,259.4 crore across multiple price points. Carlyle’s stake fell from 61.31 percent (as of June 2026) to 50.43 percent.
The market reacted sharply. Viyash shares slipped 5.37 percent to Rs 263.4 on the National Stock Exchange, trading in high volumes. The open‑market sale triggered a sell‑side pressure that was quickly countered by a group of institutional buyers.
Institutional Buying Surge and Market Impact Six investors purchased the shares Carlyle sold. Kotak Mahindra AMC bought 24.69 lakh shares for Rs 64.96 crore at Rs 263.1 per share, while Bandhan Mutual Fund acquired 28.43 lakh shares for Rs 74.8 crore at Rs 263.1. Edelweiss Mutual Fund took 25.92 lakh shares for Rs 70 crore, Panvira India Innovation Fund snapped up 11.11 lakh shares for Rs 30 crore, and both S Gupta Homes and Aagam Investments bought 9.26 lakh shares each for Rs 25 crore at Rs 270.
Other notable transactions included Gaja Capital’s IPO rally, where Invesco Mutual Fund added 85.95 lakh shares (6.09 percent of paid‑up equity) for Rs 157.8 crore, and American Funds sold 67.64 lakh shares of Avenue Supermarts for Rs 2,537.12 crore at Rs 3,750.58 per share. Amansa Holding and Goldman Sachs Asia also divested shares in Standard Engineering Technology and TCC Concept respectively.
Overall, the day highlighted the liquidity and institutional appetite in the pharma and retail sectors, with Carlyle’s exit paving the way for new investors to step in and reshape Viyash Scientific’s shareholder base.